![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » ADVANCED VIRAL ADDS FOURTH SITE FOR ITS PHASE II TRIAL
ADVANCED VIRAL ADDS FOURTH SITE FOR ITS PHASE II TRIAL
Advanced Viral Research has added Queens Medical Associates in New York as a new clinical site for its Phase II, multicenter clinical trial of AVR118 in the U.S. Other participating sites include North Shore University Hospital of New York and Jacobi Medical Center, both in New York, and the Medical Center of Vincennes in Indiana.
The study is examining the safety, tolerability and efficacy of AVR118 in patients with advanced cancer who are suffering from symptoms of progressive disease, including weight loss, fatigue and loss of appetite. The primary objective of the study is to explore the effect of AVR118 on weight, appetite, performance status and other measures of quality of life related to advanced malignancies as compared to patients not receiving AVR118. The trial is being coordinated through The Biomedical Research Alliance of New York network of hospitals.
The Phase II, multicenter, randomized, double-blind study is designed to evaluate the effect of a 4.0 ml dose of AVR118 administered to patients with systemic symptoms related to advanced cancers who are not candidates for, or who do not wish to receive, chemotherapy. Patients will be on the drug for three weeks in order to compare treatment versus no treatment, after which the results of the study will be analyzed. Those who did not receive AVR118 during the first three weeks will be permitted to take the drug for three weeks. Patients who appear to benefit from treatment may be eligible to remain on AVR118, generating longer-term safety data.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct